Upadacitinib
| Clinical data | |
|---|---|
| Pronunciation | /juˌpædəˈsɪtɪnɪb/ ew-PAD-ə-SI-ti-nib |
| Trade names | Rinvoq |
| Other names | ABT-494 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a619051 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Janus kinase (JAK) inhibitor |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 52% |
| Metabolism | Liver (CYP3A major, CYP2D6 minor) |
| Metabolites | M4, an acyl glucuronide |
| Elimination half-life | 9–14 (6–15) hours |
| Excretion | Mainly unchanged in feces (38%) and urine (24%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H19F3N6O |
| Molar mass | 380.375 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Upadacitinib, sold under the brand name Rinvoq, is a medication used for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and axial spondyloarthritis. Upadacitinib is a Janus kinase (JAK) inhibitor that works by blocking the action of enzymes called Janus kinases. These enzymes are involved in setting up processes that lead to inflammation, and blocking their effect brings inflammation in the joints under control.
Common side effects include upper respiratory tract infections (common cold, sinus infections), nausea, cough, and fever.
Upadacitinib was approved for medical use in both the United States and the European Union in 2019.